imprint



Theranostics with OPS201 and OPS202

Abstracts

14/10/22 Higher Tumour Uptake and Residence Time …

14/10/19 [68Ga]-OPS202 targeting somatostatin receptors …

Imprint

OctreoPharm Sciences GmbH

Biomedical Research Campus Berlin-Buch
Robert-Roessle-Strasse 10
13125 Berlin
GERMANY

Phone+49 (0)30 94893360
Fax+49 (0)30 94893364
Emailinfo(at)octreopharm.com

www.octreopharmsciences.com

Geschaeftsfuehrer / Managing Director:

Dr. Hakim Bouterfa

Eintragung im Handelsregister / Incorporated:

Amtsgericht Charlottenburg / Trade Court of Charlottenburg
HRB 133718 B

UID DE274428348

Picture Credits

Slider and Site Development Products: Guido Alfs / spreepunkt
Slider and Site Company: istockphoto.com/nicolas_
Site Team: ©Wolfgang Siesing
Slider and Site Meet OPS: Hamburg, ©M. Johannsen – fotolia.com
Slider and Site Meet OPS: Austin, Texas, ©kennytong – fotolia.com
Slider and Sites Jobs: ©Corepics VOF – shutterstock.com
Slider and Site News + Media: ©Daniel Wagner
Slider and Site Contact: ©BBB GmbH

Webdesign

bb BERLIN
created with WordPress


OctreoPharm Sciences GmbH

The creativity of oncologists, radiochemists and nuclear medicine physicians gave the impulses.

We just make it happen.

A company of IPSEN

The OctreoPharm Sciences GmbH is a company of IPSEN PHARMA SAS, a French pharmaceutical concern.

For more information about IPSEN visit the website of the group >>more